Biomarkers in multiple sclerosis: an update for 2014

Autores de IIS La Fe

• Raquel Martin Morales

  Autor

• 

  Bonaventura Casanova Estruch

  Autor

Participantes ajenos a IIS La Fe

• Fernandez O
• Rovira A
• Llufriu S
• Vidal-Jordana A
• Fernandez-Sanchez VE
• Alvarez-Cermeno JC
• Izquierdo G
• Arroyo-Gonzalez R
• Rodriguez-Antiguedad A
• Montalban X

Grupos

• Investigación en Neuroinmunología y Esclerosis Múltiple

  

  Leader

  Bonaventura Casanova Estruch

Abstract

Multiple sclerosis is a chronic, demyelinating and inflammatory disease of the central nervous system that mainly affects young adults. It is characterised by processes involving inflammation, demyelination and axonal destruction, and as a result the pathogenic aspects and response to treatment of the disease vary widely. It is therefore difficult to establish a prognosis for these patients or to determine the effectiveness of the different drugs that are employed. Current clinical research into the development of new biomarkers has advanced a great deal in recent years, especially in the early stages of the disease. Yet, it is essential to further our knowledge about novel markers of the disease, and not only in the more advanced stages, so as to be able to stop disability from progressing and to establish new therapy regimens in these patients. This review presents an update on the information available about the biomarkers that are currently validated and used in multiple sclerosis, together with the possible candidates for utilisation in routine clinical practice.

Keywords

• Biomarkers; Cerebrospinal fluid; Disability; Multiple sclerosis; Outbreaks; Update